Johnson & Johnson

Johnson & Johnson logo

Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation focused on developing and producing pharmaceutical prescription drugs and medical device technologies. The company aims to improve health outcomes through innovative solutions.

Positive signals

Johnson & Johnson's ESG management is rated as 'Strong' by Sustainalytics, indicating robust programs, practices, and policies for managing material ESG issues.

Johnson & Johnson received an ESG score of 68/100 from Sustainalytics, reflecting its commitment to environmental responsibility, social impact, and strong governance practices.

Johnson & Johnson achieved a Sustainalytics ESG Risk Rating of 22.5 (Medium risk) as of May 2025, ranking 114th out of 843 companies in its industry, with a 'Strong' management score for ESG material risks.

By 2023, all Johnson & Johnson facilities in the United States, Canada, and Europe operated exclusively on renewable energy, marking a significant step toward reducing the company’s climate impact.

Johnson & Johnson was recognized as a 2022 Fortune World's Most Admired Company and pharmaceutical industry leader, highlighting its reputation for corporate responsibility and governance.

Concerns

Asbestos contamination in talcum powder products

CRITICAL
Source

Legal challenges regarding product safety and marketing practices

Johnson & Johnson's environmental impact remains a concern, with a negative score of -2.02 for environment and -0.85 for GHG emissions in MarketBeat's 2025 ESG profile, indicating ongoing challenges in reducing emissions and environmental footprint.

Johnson & Johnson has faced high-profile product safety controversies in recent years, contributing to a 'Highest Controversy Level' as of June 2025 according to Morningstar, reflecting ongoing reputational and legal risks.

Mismanagement of health plan costs leading to higher employee expenses